Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular and biological mechanisms without systematic review methodology or new human clinical data.
PubMed 21968328 · doi:10.1016/j.yjmcc.2011.09.014
What was done
This narrative review synthesized literature examining the cholesterol-independent pleiotropic mechanisms of statins, focusing specifically on the pathways responsible for the modulation, upregulation, and activation of endothelial nitric oxide synthase (eNOS).
What was found
The abstract provides no quantitative data or numerical effect estimates. It outlines three primary mechanistic pathways: statins upregulate eNOS by inhibiting isoprenoid synthesis and preventing small GTPase Rho isoprenylation; statins activate eNOS via the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway; and statins augment eNOS activity by down-regulating caveolin-1 expression in the vascular endothelium.
Why it matters
It outlines how statin-mediated stimulation of nitric oxide production contributes to vasodilation, anti-inflammatory, and anti-platelet actions independently of low-density lipoprotein cholesterol lowering.
Limits
As a narrative review, it lacks systematic search criteria, meta-analytic pooling, and risk-of-bias evaluation. The claims are derived from preclinical and mechanistic literature rather than direct clinical outcome measurements.
Cited by
- supports Statins induce endothelial nitric oxide synthase expression, dilating blood vessels and reducing vascular inflammation.